SPOTLIGHT: Lilly phasing out some insulin drugs

Eli Lilly is phasing out four insulin products with low or falling sales. About 68,000 diabetics will have until the end of the year to find other products as remaining inventories are depleted. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.